CELC
Celcuity Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 25 Celcuity announced strong clinical results from the PIK3CA wild-type…
- Mar 31 ▼ 1 insider sell $330.8K at $110.27
- May 1 ▲ Celcuity announced positive topline Phase 3 VIKTORIA-1 results for g…
- May 4 ▼ 2 insiders sell $4.8M at $140.62
- Jun 2 ▲ Celcuity announced detailed Phase 3 VIKTORIA-1 results showing its g…
- Jun 30 ▲ 8 funds open new positions (13F)
- Jul 14 ▼ 1 insider sell $317.8M at $102.50
- Jul 14 ▲ Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/H…
- Oct 22 Cantor Fitzgerald initiates
- Oct 24 ▲ Celcuity presented new subgroup analyses from the Phase 3 VIKTORIA-1…
- Oct 24 FDA: Celcuity Presents Updated Results from the PIK3CA MT Cohor…
- Nov 9 FDA: Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (…
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $322.9M.
- InstitutionsBULLISH
Q2 2026: 49 added (8 new), 15 trimmed or exited. Largest new: Hood River Capital Management $65.7M, Fuller & Thaler Asset Management, $53.8M.
- AnalystsBULLISH
18 of 19 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +0.5% to 10.30M shares. 5.8 days to cover, ≈21.0% of shares.
- TrendRANGE
16% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | ADD | $204.6M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | $153.9M |
| TORONTO DOMINION BANK | ADD | $131.7M |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | $94.8M |
| Point72 Asset Management, L.P. | DOUBLED | $68.1M |
| Hood River Capital Management LLC | NEW | $65.7M |
| FMR LLC | DOUBLED | $57.4M |
| Holocene Advisors, LP | ADD | $55.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +148%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 6, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 2, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 22, 2026 | Cantor Fitzgerald INITIATE | Overweight |
| Oct 21, 2026 | TD Cowen REITERATE | Buy |
| Sep 30, 2026 | Needham MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Furcht Leo Director Oct 7, 2026 | EXERCISE | $1.9K |
GRYSKA DAVID W Director Oct 1, 2026 | AWARD | 893 sh |
Sullivan Brian F. Chief Executive Officer Aug 14, 2026 | AWARD | 120,000 sh |
Laing Lance G. Chief Science Officer Aug 14, 2026 | AWARD | 10,000 sh |
Hahne Vicky Chief Financial Officer Aug 14, 2026 | AWARD | 16,000 sh |
Laing Lance G. Chief Science Officer Aug 14, 2026 | AWARD | 20,000 sh |
Hahne Vicky Chief Financial Officer Aug 14, 2026 | AWARD | 10,000 sh |
Sullivan Brian F. Chief Executive Officer Aug 14, 2026 | AWARD | 80,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$1.08 | -$1.08–-$1.08 | -16.1% | $31.9M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
19 filings · 7 press releases · 6 bullish · 2 bearish · 2 mixed · 9 neutral- NEUTRAL SC 13G/ANov 16, 2026
Bank of America Corp filed an amended Schedule 13G disclosing a 3.7% passive stake in Celcuity Inc., up from a prior filing. The filing is routine and provides no new directional signal.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Avoro Capital Advisors filed an amended Schedule 13G disclosing a 3.07% passive stake in Celcuity, unchanged from the prior filing. The filing is routine and provides no new directional signal.
🔒 Fresh report (last 24h), subscribers only
- BULLISH PRESS RELEASENov 9, 2026
Celcuity announced FDA acceptance of its sNDA for REVTORPYK (gedatolisib) in HR+/HER2- advanced…
Monitor PDUFA date June 25, 2027 for approval decision; watch for launch metrics and revenue ramp from the existing wild-type approval as a read-through for mutant cohort commercial potential.
- NEUTRAL 8-KNov 5, 2026
Celcuity reported Q3 2026 results with no product revenue as REVTORPYK shipments began on Sept 30…
Monitor Q4 2026 for first product revenue recognition and prescription trends; the sNDA for the PIK3CA mutant label expansion is a key catalyst; watch for global regulatory submissions later this…
All CELC filing & press-release reports (26)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- PRESS-RELEASE reportNov 9, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- INST-CLUSTER reportNov 2, 2026
- PRESS-RELEASE reportOct 24, 2026
- 3 reportOct 5, 2026
- 8-K reportOct 2, 2026
- 8-K reportSep 30, 2026
- INST-CLUSTER reportSep 22, 2026
- 8-K reportAug 26, 2026
- 144 reportJul 14, 2026
- PRESS-RELEASE reportJul 14, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 8, 2026
- 424B5 reportJun 5, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportJun 3, 2026
- 424B5 reportJun 3, 2026
- 8-K reportJun 2, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMay 7, 2026
- 144 reportMay 4, 2026
- PRESS-RELEASE reportMay 1, 2026
- PRESS-RELEASE reportMar 25, 2026